# Peroxitech Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/peroxitech-therapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.peroxitech.com
- Total disclosed funding: $25M
- Latest round: Series A (Dec 13, 2022)
- Investors on record: 1

## About

Based in Pennsylvania, US, and founded by Aron Fisher, Sheldon I. Feinstein, and Thomas Han (CEO), Peroxitech Inc., doing business as Peroxitech Therapeutics is a biopharmaceutical company that develops PIP-2 to repair and reverse acute lung injury (ALI) by addressing the cytokine storm cascade pathway. In May 2021, Peroxitech Therapeutics raised Seed funding led by investor Xontogeny, LCC.

The company creates biopharmaceuticals based on its lead molecule, PIP-2, which helps to reduce reactive oxygen species (ROS) buildup in the lungs resulting from respiratory failure with hypoxemia and tissue acidosis, as well as to treat acute lung injury.

The company intends to use the May 2021 funding to advance the new treatment of acute lung injury and additional toxicology preclinical trials.

## Funding rounds

- Series A, Dec 13, 2022, $25M — Perceptive Advisors

## Investors

- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A